Obagi C Rx System

Obagi-C® Rx System— quick and dramatic improvements,

Physician-dispensed skincare system Obagi offers two customised systems designed to treat all skin types ‑ Normal to Dry and Normal to Oily A clinically proven, early intervention skin care system. Supply last approximately 4-6 months.

• Reduce hyperpigmentation and improve skin tone with prescription 4% hydroquinone

• Help address other signs of skin ageing with additional key ingredients – Achieve softer, smoother, and more radiant-looking skin – Visibly reduce the appearance of fine lines and wrinkles The Obagi-C® Rx System provides ideal skincare for improving:

• Discolouration, age spots, and unevenness of skin tone

• The appearance of fine lines and wrinkles Baseline Week 12

Obagi-C® Rx delivers

• Visible improvements for all skin types,

* – 97% of patients reported an overall improvement in the appearance of their skin

– 93% of patients had smoother, softer, more radiant‑looking skin

– 90% of patients reported more evenly toned skin

– 87% of patients reported a visible reduction in fine lines and wrinkles

– Results are seen in as early as 4 weeks

• Lasting Vitamin C power

–Obagi‑C® Rx Clarifying Serum delivers more L-ascorbic acid into the skin at 24 hours than SkinCeuticals Phloretin CF


Important Safety Information for C-Clarifying Serum and C-Therapy Night Cream (contain 4% hydroquinone)

CONTRAINDICATIONS: People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

WARNINGS: Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, the patient should rinse eyes, nose, mouth, or lips with water and contact physician. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity. Contains sodium metabisulfite, a sulfite that may cause allergic‑type reactions including anaphylactic symptoms and life‑threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS (ALSO SEE WARNINGS): Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment. Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated. Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother. Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established. Use of this product should be discontinued if hypersensitivity to any of the ingredients is noted. To purchase the Obagi-C® Rx System that’s right for you, talk to your physician today.